

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
02 AUG 14 PM 3:32

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Bennett, Turner & Coleman, LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 1900 K Street NW, Suite 750 Washington, DC 20006			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Albert Cacozza	Telephone 202-833-4500	E-mail (optional)	5. Senate ID # 53298-1
7. Client Name <input type="checkbox"/> Self Novartis Pharmaceuticals Corporation			6. House ID # 349760

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date June 30, 2002

11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>20,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6113 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
---	---

Signature _____

Printed Name and Title Terry S. Coleman, Partner

Registrant Name Bennett, Turner & Coleman, LLP Client Name Novartis Pharmaceuticals Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for oral anti-cancer therapies
H.R. 1624; S. 913

17. House(s) of Congress and Federal agencies contacted

Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sam Turner, Partner	
Elizabeth Goss, Partner	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

To the degree that public policies, either laws or regulations, commercially benefit Novartis Pharmaceutic Corporation, so too Novartis AG will benefit. Novartis AG is the parent company of Novartis Pharmaceuti Corporation and the parent benefits in the commercial success of its subsidiary.

Signature *Terry S. Coleman* Date August 14, 2002

Printed Name and Title Terry S. Coleman, Partner

